3,4-dihydroxyphenylacetic acid has been researched along with Substance-Related Disorders in 15 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
Substance-Related Disorders: Disorders related to substance use or abuse.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combined decrease in Ago2 and increases in Nurr1 and Pitx3 might represent some of the mechanisms that served to protect against accumbal TH regulation observed in morphine withdrawn rats, which may be critical for DA bioavailability to influence behaviour." | 1.39 | Morphine administration modulates expression of Argonaute 2 and dopamine-related transcription factors involved in midbrain dopaminergic neurons function. ( García-Pérez, D; Laorden, ML; Milanés, MV; Núñez, C; Sáez-Belmonte, F, 2013) |
| " Taken together, our data indicate that chronic use of stanozolol significantly affects brain monoamines leading to neurochemical modifications possibly involved in depression and stress-related states." | 1.38 | Neurochemical consequence of steroid abuse: stanozolol-induced monoaminergic changes. ( Colaianna, M; Cuomo, V; Morgese, MG; Schiavone, S; Trabace, L; Tucci, P; Zotti, M, 2012) |
| "5-h intervals) 12 h prior to the MDMA dosing regimen (20 mg/kg x 3 at 2-h intervals) aggravated the MDMA-induced dopaminergic toxicity." | 1.35 | Ketamine pretreatment exacerbated 3,4-methylenedioxymethamphetamine-induced central dopamine toxicity. ( Cherng, CG; Ho, MC; Ke, JJ; Tsai, CW; Tsai, YP; Yu, L, 2008) |
| "We have demonstrated that chronic administration of neuropeptide FF (NPFF) into the lateral ventricle potentiated the behavioral sensitization to amphetamine." | 1.30 | Neuropeptide FF potentiates the behavioral sensitization to amphetamine and alters the levels of neurotransmitters in the medial prefrontal cortex. ( Chen, JC; Huang, YK; Li, JY; Liang, KW, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Krasnova, IN | 1 |
| Chiflikyan, M | 1 |
| Justinova, Z | 1 |
| McCoy, MT | 1 |
| Ladenheim, B | 1 |
| Jayanthi, S | 1 |
| Quintero, C | 1 |
| Brannock, C | 1 |
| Barnes, C | 1 |
| Adair, JE | 1 |
| Lehrmann, E | 1 |
| Kobeissy, FH | 1 |
| Gold, MS | 1 |
| Becker, KG | 1 |
| Goldberg, SR | 1 |
| Cadet, JL | 1 |
| Rodríguez-Arias, M | 1 |
| Valverde, O | 1 |
| Daza-Losada, M | 1 |
| Blanco-Gandía, MC | 1 |
| Aguilar, MA | 1 |
| Miñarro, J | 1 |
| Ke, JJ | 1 |
| Ho, MC | 1 |
| Cherng, CG | 1 |
| Tsai, YP | 1 |
| Tsai, CW | 1 |
| Yu, L | 1 |
| Tucci, P | 1 |
| Morgese, MG | 1 |
| Colaianna, M | 1 |
| Zotti, M | 1 |
| Schiavone, S | 1 |
| Cuomo, V | 1 |
| Trabace, L | 1 |
| García-Pérez, D | 1 |
| Sáez-Belmonte, F | 1 |
| Laorden, ML | 1 |
| Núñez, C | 1 |
| Milanés, MV | 1 |
| Okamoto, R | 1 |
| Itoh, Y | 1 |
| Murata, Y | 1 |
| Kobayashi, D | 1 |
| Hosoi, M | 1 |
| Mine, K | 1 |
| Gardner, EL | 1 |
| Liu, X | 1 |
| Paredes, W | 1 |
| Giordano, A | 1 |
| Spector, J | 1 |
| Lepore, M | 1 |
| Wu, KM | 1 |
| Froimowitz, M | 1 |
| Birgner, C | 1 |
| Kindlundh-Högberg, AM | 1 |
| Nyberg, F | 1 |
| Bergström, L | 1 |
| Chen, JC | 1 |
| Li, JY | 1 |
| Liang, KW | 1 |
| Huang, YK | 1 |
| Scearce-Levie, K | 1 |
| Chen, JP | 1 |
| Gardner, E | 1 |
| Hen, R | 1 |
| Drouin, C | 1 |
| Darracq, L | 1 |
| Trovero, F | 1 |
| Blanc, G | 1 |
| Glowinski, J | 1 |
| Cotecchia, S | 1 |
| Tassin, JP | 1 |
| See, RE | 1 |
| Adams-Curtis, L | 1 |
| Chapman, MA | 1 |
| Piazza, PV | 1 |
| Rougé-Pont, F | 1 |
| Deminière, JM | 1 |
| Kharoubi, M | 1 |
| Le Moal, M | 1 |
| Simon, H | 1 |
| Clarren, SK | 1 |
| Astley, SJ | 1 |
| Bowden, DM | 1 |
| Lai, H | 1 |
| Milam, AH | 1 |
| Rudeen, PK | 1 |
| Shoemaker, WJ | 1 |
| Seiden, LS | 1 |
15 other studies available for 3,4-dihydroxyphenylacetic acid and Substance-Related Disorders
| Article | Year |
|---|---|
CREB phosphorylation regulates striatal transcriptional responses in the self-administration model of methamphetamine addiction in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Central Nervous System Stimulants; Conditioning, Operant; C | 2013 |
Assessment of the abuse potential of MDMA in the conditioned place preference paradigm: role of CB1 receptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Brain; Conditioning, Operant; Disease | 2013 |
Ketamine pretreatment exacerbated 3,4-methylenedioxymethamphetamine-induced central dopamine toxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transpo | 2008 |
Neurochemical consequence of steroid abuse: stanozolol-induced monoaminergic changes.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Depression; Dopamine; Hippocampus; Homovan | 2012 |
Morphine administration modulates expression of Argonaute 2 and dopamine-related transcription factors involved in midbrain dopaminergic neurons function.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Argonaute Proteins; Body Weight; Dopamine; Drug Implants; G | 2013 |
Reduction of group II metabotropic glutamate receptors during development of benzodiazepine dependence.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzodiazepines; Cerebral Cortex; Dopamine; Flumazenil; GAB | 2013 |
A slow-onset, long-duration indanamine monoamine reuptake inhibitor as a potential maintenance pharmacotherapy for psychostimulant abuse: effects in laboratory rat models relating to addiction.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Cocaine; Dialysis; | 2006 |
Altered extracellular levels of DOPAC and HVA in the rat nucleus accumbens shell in response to sub-chronic nandrolone administration and a subsequent amphetamine challenge.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Anabolic Agents; Animals; Dopamine; Dopamine Uptake Inh | 2007 |
Neuropeptide FF potentiates the behavioral sensitization to amphetamine and alters the levels of neurotransmitters in the medial prefrontal cortex.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Dopamine; Drug Synergism; Hippocampus; Homovan | 1999 |
5-HT receptor knockout mice: pharmacological tools or models of psychiatric disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aggression; Animals; Behavior, Animal; Cocaine; Disease Models, Anim | 1999 |
Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic alpha-Antagonists; Animals; Brain; Central Nervous System | 2002 |
Assessment of dopamine release by in vivo microdialysis in the nucleus accumbens of rats following acute and chronic administration of desipramine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Desipramine; Dialysis; Dopamine; Homovanillic Acid; Hydroxy | 1992 |
Dopaminergic activity is reduced in the prefrontal cortex and increased in the nucleus accumbens of rats predisposed to develop amphetamine self-administration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Cerebral Cortex; Corpus Striatum; Dopamine; Hy | 1991 |
Neuroanatomic and neurochemical abnormalities in nonhuman primate infants exposed to weekly doses of ethanol during gestation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Drinking; Animals; Brain; Corpus Striatum; Ethanol; Eye; Fem | 1990 |
Methamphetamine: toxicity to dopaminergic neurons.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Dopamine; Guinea Pigs; Hydroxydopamines; K | 1985 |